Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada
Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt DUBLIN, Ireland and […]